Novel respirable rifampicin-curcumin loaded nanoparticles against  Mycobacterium tuberculosis infection.

MARTINENA CAMILA; MARTIN CANDELA; RIEDEL J; AMIANO, N; CHIAPPETTA, DIEGO A.; PALMAS L; DONNOLI L; MORELLI P; BERNABEU, E; MORETTON, M; ALARCON L; RIEMMER C; PELLEGRINI, J; GARCIA, VE; TATEOSIAN, NANCY L.

Congreso; LXIIX Reunión Anual de la Sociedad Argentina de Inmunología; 2020

Sociedad Argentina de Inmunologia

Rifampicin (RIF) is one of the most powerful and effective first line drug employed in the treatment of Mycobacterium tuberculosis (Mtb) infection. With the worldwide emergence of highly drug-resistant tuberculosis (TB), novel agents that have direct antimycobacterial effects or that enhance host immunity are urgently needed. It was described the immunomodulatory anti-TB effects of Curcumin (CUR), a potent anti-oxidant and apoptosis inducer compound. We develop novel RIF-CUR nanoparticles (RIF-CUR NP) with improved drug aqueous solubility and stability for inhalator administration. Then, we analyzed by confocal microscopy the in vitro uptake of CUR-NP (40 µg/ml) in human macrophages (derived from PBMCs) at different time points (1h, 18h, 24h and 48h). We found a higher drug cellular uptake levels (intensity/ area) for Mtb antigen-stimulated cells (0.25±0.04) than unstimulated control (0.07±0.02) over 18 hours (ANOVA test, p